APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION

The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system. Randomized trials showed a beneficial effect of phosphodiesterase type 5 (PDE-5) inhibitors on vasc...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Martynyuk, Z. H. Dadacheva, V. M. Paramonov, O. A. Arkhipova, S. N. Nakonechnikov, I. Ye. Chazova
Format: Article
Language:Russian
Published: InterMedservice 2015-06-01
Series:Евразийский Кардиологический Журнал
Subjects:
Online Access:https://www.heartj.asia/jour/article/view/5633
Tags: Add Tag
No Tags, Be the first to tag this record!